股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司*（於開曼群島註冊成立的有限公司）*僅供識別 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 6,000,000,000 | USD | 0.000008333333 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 6,000,000,000 | U ...

Summary of Key Points Core Viewpoint - As of September 4, 60 stocks reached their 52-week highs, indicating a positive market trend with notable performances from specific companies such as Gaoshan Enterprises, Milan Station, and Yongyi International [1]. Group 1: 52-Week Highs - Gaoshan Enterprises (00616) achieved a closing price of 0.350 with a peak of 0.370, marking a high rate of 60.87% [1]. - Milan Station (01150) closed at 0.340, reaching a high of 0.360, with a high rate of 44.00% [1]. - Yongyi International (01218) had a closing price of 3.830 and a peak of 4.100, resulting in a high rate of 17.14% [1]. - Other notable stocks include: - Cheng Tian Jia He (01132) with a high rate of 16.49% [1]. - San Ye Cao Biotechnology - B (02197) with a high rate of 16.46% [1]. - Capital Financial Holdings (08239) with a high rate of 16.28% [1]. Group 2: 52-Week Lows - Wanma Holdings (02935) reached a low of 0.034, reflecting a decline of 25.00% [2]. - Rongyang Industrial (02078) had a closing price of 0.160, with a low of 0.069, indicating a drop of 15.85% [2]. - Energy International Investment (00353) closed at 0.295, reaching a low of 0.275, down by 12.70% [2]. - Other significant declines include: - Qianli Holdings (08367) with a drop of 12.00% [2]. - Yunkang Group (02325) with a decline of 10.71% [2]. - Wanwei International (00167) down by 7.41% [2].

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) experienced a decline of 3.38% on September 4, with a trading volume of 1.427 billion yuan. The fund has shown significant growth in both share volume and total assets since its inception in January 2024 [1][2]. Group 1: Fund Performance - The Hong Kong Innovative Drug ETF (159567) was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1]. - As of September 3, 2024, the fund's latest share volume was 6.668 billion shares, and its total assets reached 6.724 billion yuan. This represents an increase of 1586.48% in share volume and 1679.83% in total assets compared to December 31, 2023, when the share volume was 395 million shares and total assets were 378 million yuan [1]. Group 2: Trading Activity - Over the past 20 trading days, the cumulative trading amount for the Hong Kong Innovative Drug ETF (159567) was 33.138 billion yuan, with an average daily trading amount of 1.657 billion yuan. Since the beginning of the year, the cumulative trading amount over 165 trading days was 185.061 billion yuan, averaging 1.122 billion yuan per day [1]. Group 3: Fund Holdings - The current fund manager of the Hong Kong Innovative Drug ETF (159567) is Ma Jun, who has managed the fund since its inception, achieving a return of 99.52% during this period [2]. - Key holdings in the fund include: - Innovent Biologics (9.52% holding, 2.60 billion yuan market value) - WuXi Biologics (9.47% holding, 2.58 billion yuan market value) - BeiGene (8.73% holding, 2.38 billion yuan market value) - CanSino Biologics (7.62% holding, 2.08 billion yuan market value) - China National Pharmaceutical Group (7.17% holding, 1.96 billion yuan market value) - CSPC Pharmaceutical Group (6.34% holding, 1.73 billion yuan market value) - 3SBio (5.83% holding, 1.59 billion yuan market value) - Hansoh Pharmaceutical (4.54% holding, 1.24 billion yuan market value) - Zai Lab (2.86% holding, 781.055 million yuan market value) [2].

Market Overview - On September 3, the Hang Seng Index fell by 0.6% to close at 25,343 points, while the Hang Seng Tech Index dropped by 0.8% to 5,683 points, indicating weak market sentiment[1] - The total market turnover was HKD 267.6 billion, significantly lower than the previous two trading days which exceeded HKD 300 billion, reflecting increasing market caution[1] - Net inflow from the Stock Connect was HKD 5.51 billion, showing a decrease in enthusiasm from mainland investors[1] Sector Performance - Major tech stocks declined, with Xiaomi down 2.1%, NetEase down 1.8%, and Alibaba, Tencent, and Meituan also closing lower[1] - The financial sector was notably weak, with ICBC down 1.2% and China Pacific Insurance down 2.5%[1] - Conversely, biopharmaceutical stocks performed well, with WuXi AppTec rising over 9% and Hengrui Medicine up over 8%[1] Global Economic Indicators - The 30-year bond yields in Germany, France, and the Netherlands reached their highest levels since the 2011 Eurozone crisis, while the UK’s 30-year bond yield hit its highest since 1998[1] - The US 30-year bond yield approached the psychological level of 5%, contributing to rising global debt concerns and increased risk aversion, pushing gold prices to new historical highs[1] US Manufacturing Sector - The ISM Manufacturing PMI for August slightly increased to 48.7%, remaining below the neutral line for six consecutive months, with the output index dropping to 47.8%[2] - The new orders index rose to 51.4%, marking the first time since January that it surpassed the neutral line, indicating a faster recovery in domestic demand compared to external demand[2] Company-Specific Insights - Haijia Medical reported a 16.5% year-on-year decline in revenue to RMB 1.99 billion for the first half of 2025, with net profit down 36.2% to RMB 250 million, attributed to a challenging macro environment and stricter medical insurance controls[5][6] - Despite the revenue decline, Haijia Medical's accounts receivable decreased by 9.1%, and net cash from operating activities increased by 29.9%, indicating potential recovery signs[6] Future Outlook - The long-term outlook for the oncology sector in private healthcare is positive due to supportive policy changes, including immediate settlement of medical insurance funds and innovation in commercial insurance drug directories[8] - The target price for Haijia Medical is set at HKD 13.55, maintaining a "neutral" rating, with revenue forecasts for 2025-2027 adjusted downwards by 15.5%, 12.9%, and 13.2% respectively[9]

Group 1: Market Overview - The Hong Kong stock market continues to experience fluctuations, with the Hang Seng Index closing at 25,343.43, down 153 points or 0.6%, after a day of volatility [3] - The trading volume decreased to below 30 billion HKD, indicating reduced market activity [3] Group 2: Macro & Industry Dynamics - The sustainable debt market in Hong Kong is projected to grow steadily, with an estimated issuance of 34.3 billion USD in the first half of 2025, representing a 15% year-on-year increase [6] - The total issuance of green and sustainable debt in Hong Kong is expected to reach 84.4 billion USD in 2024, a significant 61% increase from the previous year [6] - Goldman Sachs forecasts a substantial increase in global merger and acquisition (M&A) activity, predicting a total deal volume of approximately 3.1 trillion USD in 2025, rising to 3.9 trillion USD in 2026 [8] Group 3: Company News - WuXi AppTec plans to raise 2.731 billion HKD through a share placement at a price of 58.85 HKD per share, with approximately 90% of the proceeds allocated to expanding service capacity and production capabilities [10] - Zijin Mining International is expected to raise at least 3 billion USD (approximately 23.4 billion HKD) in its Hong Kong listing, which is 50% higher than the initial estimate [11] - Henderson Land Development's CFO indicated that residential property prices in Hong Kong are nearing a bottom, with expectations of increased demand due to immigration [12]

Core Insights - WuXi Biologics reported a 16.1% year-on-year revenue growth in the first half of 2025, reaching 9.95 billion yuan, with net profit attributable to shareholders increasing by 56.1% to 2.34 billion yuan [1] - Adjusted net profit grew by 6.2% year-on-year to 2.39 billion yuan, aligning with expectations, while the overall gross margin improved by 3.7 percentage points to 42.7% [1] Revenue Breakdown - IND pre-service revenue surged by 35.2% year-on-year to 4.15 billion yuan in the first half of 2025 [2] - Early-stage project revenue declined by 29.7% due to large projects transitioning to later development stages, while Phase III and commercial project revenue increased by 24.9% [2] - Revenue from the U.S. grew by 20.1%, accounting for 60.5% of total revenue, while Europe and China saw revenue growth of 5.7% and a decline of 8.5%, respectively [2] Project Pipeline - The company added 86 new projects in the first half of 2025, with over half coming from the U.S. and an improved contribution from China [3] - The total project count reached 864, including 67 Phase III projects and 24 commercial projects, indicating potential for future revenue growth [3] - Adjusted net profit forecasts for 2025 and 2026 were revised down to 4.90 billion yuan and 5.50 billion yuan, respectively, with a new forecast for 2027 set at 6.34 billion yuan [3]

Core Viewpoint - WuXi AppTec (02268.HK) announced a share placement at HKD 58.85 per share, aiming to raise approximately HKD 13.11 billion, with 90% of the proceeds intended for expanding service capacity and production [1][2] Group 1: Share Placement Details - The share placement involves a maximum of 22.28 million shares, with a discount of about 4.00% compared to the last trading day's closing price of HKD 61.3 per share, but a premium of approximately 2.87% over the average closing price of the previous five trading days [1][2] - The controlling shareholder, WuXi Biologics (02269.HK), subscribed to 24.134 million shares, amounting to approximately HKD 14.20 billion [1] Group 2: Company Performance and Market Position - WuXi AppTec's stock price has doubled since the first trading day of the year, reaching a historical high of HKD 61.3 per share [2][3] - The company reported revenue and net profit of CNY 2.701 billion and CNY 746 million for the first half of the year, representing year-on-year growth of 62.2% and 52.7%, respectively, driven by the active bioconjugate drug market [3] - The company has a backlog of unfulfilled orders amounting to USD 1.329 billion, a year-on-year increase of 57.9% [3] Group 3: Industry Outlook - The global ADC (Antibody-Drug Conjugate) market is projected to grow at a compound annual growth rate (CAGR) of 34% from 2020 to 2024 and 31% from 2024 to 2030, potentially reaching USD 66.2 billion by 2032 [5] - The outsourcing rate for ADC production is expected to be around 60%, significantly higher than the 34% for biopharmaceuticals, indicating a strong demand for WuXi AppTec's services [5]

Group 1 - The company, WuXi AppTec Co., Ltd. (2268.HK), announced two fundraising arrangements totaling HKD 27.14 billion (USD 3.48 billion) [1] - The company plans to issue up to 22.277 million new shares at HKD 58.85 per share, representing a discount of approximately 4%, with a net amount of about HKD 1.3 billion, accounting for approximately 1.82% of the enlarged share capital [1] - The company has entered into a subscription agreement with its controlling shareholder, WuXi Biologics (2269.HK), which will subscribe for 24.134 million new shares at the same price, representing approximately 1.93% of the enlarged share capital, with a net amount of about HKD 1.414 billion [1] Group 2 - Approximately 90% of the proceeds will be used to expand the capabilities and capacity for bioconjugate drug services, including the construction of a new base in Singapore, expansion of the Wuxi facility, and potential overseas expansion [1] - The remaining 10% of the proceeds will be allocated for working capital and general corporate purposes [1] - Following the completion of these transactions, the shareholding of WuXi Biologics will increase from 49.81% to 50.78% [1] Group 3 - The stock price of WuXi AppTec opened higher on Wednesday, reaching HKD 64.65 at midday, an increase of 5.46% [2]

Core Viewpoint - WuXi AppTec (2268.HK) shares rose over 7% to a record high of HKD 66 amid the announcement of a new share placement to raise capital for expanding service capabilities and production capacity [1] Group 1: Capital Raising - The company plans to issue new shares at a placement price of HKD 58.85 per share, raising a total of HKD 27.31 billion, with a net amount of HKD 27.15 billion [1] - Approximately 90% of the raised funds will be used to further expand the group's service capabilities and production capacity, including clinical and commercial production of bioconjugates, active pharmaceutical ingredients, and products [1] - About 10% of the funds will be allocated for the company's working capital needs and general corporate purposes [1] Group 2: Share Placement Details - WuXi AppTec intends to place 22.77 million new shares to six subscribers, representing approximately 1.82% of the enlarged share capital [1] - The placement price of HKD 58.85 is a 4% discount compared to the previous closing price of HKD 61.3, raising HKD 13.11 billion with a net amount of HKD 13.01 billion from this portion [1] - Additionally, the company will place 24.134 million new shares to WuXi Biologics, raising HKD 14.2 billion with a net amount of HKD 14.14 billion, increasing WuXi Biologics' stake from 50.73% to 50.78% post-transaction [1]

Group 1 - The core viewpoint of the news highlights the strong performance of the Hang Seng Biotechnology ETF (513280), which has seen a nearly 2% increase and a trading volume exceeding 1.6 billion CNY, making it the only ETF in its index to achieve positive growth in shares this year [1][4] - The ETF has the lowest management fee among Hong Kong pharmaceutical ETFs, set at 0.15% per year, which may attract more investors [4] - The underlying index components of the ETF mostly showed positive performance, with notable increases from companies such as CSPC Pharmaceutical Group (up 4%) and Innovent Biologics (up over 2%) [1][2] Group 2 - Guotai Junan Securities expresses strong confidence in the pharmaceutical sector's potential for a reversal in 2025, emphasizing investment opportunities in innovative drugs and addressing unmet clinical needs [2] - Dongfang Securities notes that the first half of 2025 will see a surge in domestic innovative drugs entering international markets, which is expected to accelerate the performance of innovative drug companies [3] - The trend of "China manufacturing" shifting to "China innovation" is anticipated to drive significant growth in the pharmaceutical industry, making it an opportune time for investment [3]